agreed. excellent drug for some not all patients. horrible execution and promotion since 2012 approval.
I think we all have been extraordinarily patient up until this point but now here is where the rubber meets the road. Almost 2 years on market and Eisai as well as Arena have nothing to show for their effort, or lack thereof. Approved in 2012, with only 1 country up until South Korea recently. Come on.
The only partnership here will be between Pfizer and Eisai at selling Belviq, otherwise Belviq is doomed to fail.
Jack has been ineffective at selling Arena's prospects to Wall Street. Look no further than ACAD with similar technology, a fraction of the patents that Arena owns, and no FDA approved drug. From $2 to $30 and $3B market cap. Why? You might ask?
Oh sure another conference, another blown opportunity at increasing shareholder value. I wish they would just stop talking as no one on Wall Street believes a word they say hence another 4.5% off share price, 12% off from $4.95 in just 2 days for no good reason aside from they simply can and will take Arena down at their whim.
How exactly do you expect Eisai to step up? They clearly were not up to task with their own drug Aricept which was a flop until Pfizer made it a mega billion dollar blockbuster. Eisai is truly clueless as is Arena. Jack is an expert on ATM options and dilution however as evidenced in a float which exceeds 250M shares. One only needs to look at Arena's neighbor in San Diego, ACAD, to find answers on how to increase shareholder value reliably and consistently plus maintain institutional interest.
Forget ethics as that is irrelevant. Let's focus on effectiveness shall we?
all jack has to do is move his lips and the stock will dive. i've seen it many times.
yes so great that the price has cratered from $4.95 to $4.45 in just 2 days. we need more great news so another 104 week low is hit!
I guess we will revisit $3.20 after cc next week given that arena never ever goes up following a cc.
dont you think this would make for a more effective commercial compared to people walking around talking to their food? Earth to Eisai... Earth to Eisai?
Irrelevant as the price mearly bounced from a 104 week low of $3.20. Miserable stock performance per se. Poor execution on behalf of Arena mgmt over 12 plus years and more recently Eisai whose marketing problems began years ago with Aricept. Aricept in the hands of Eisai alone nearly flopped. Enter Pfizer and Aricept became world's best seller for many years.
Eisai's efforts are amateurish and you would think they would learn from the mistakes of past.
That is not the answer my friend. How about some accountability on behalf of management, or even Eisai for that matter. What we have here is failure beyond comprehension on every front.
Took 1 week to climb to $4.90
Took 1 day to fall back to $4.60
Unbelievable garbage. Thanks Jack! Job well done as always.